Pharmacokinetic interactions induced by content variation of major water-soluble components of Danshen preparation in rats.
OBJECTIVE
To investigate the pharmacokinetic interactions induced by content variation of the main water-soluble components of Danshen injection in rats.


METHODS
Intravenous Danshen injection (control) or Danshen injection with danshensu (DSS), protocatechuic aldehyde (PAL), salvianolic acid A (Sal A) or salvianolic acid B (Sal B) were administered to female Sprague Dawley rats. Plasma concentrations of DSS, Sal A, PAL and its oxidative metabolite protocatechuic acid (PA) were analyzed simultaneously with LC-MS/MS; concentrations of Sal B were determined by the LC-MS method. Non-compartmental pharmacokinetic parameters were calculated and compared for identifying the pharmacokinetic interactions among these components.


RESULTS
Compared with the control group, the DSS, Sal A, and Sal B groups had significant increases in AUC(0-infinity) in response to elevated concentrations of PAL (by 78.1%, 51.0%, and 82.9%, respectively), while the clearances (CL) were markedly reduced (by 42.5%, 32.9%, and 46.8%, respectively). Similarly, Sal A increased the AUC(0-infinity) of DSS and Sal B (26.7% and 82.4%, respectively) and substantially decreased their clearances (21.4% and 45.6%, respectively). In addition, the pharmacokinetics of DSS and Sal B were significantly affected by the content variation of the other major components; the AUC(0-infinity) increased by 45.1% and 52.1%, respectively, the CL dropped by 29.6% and 27.1%, respectively, and the T(1/2) was decreased by 22.0% and 19.6%, respectively.


CONCLUSIONS
Complex, extensive pharmacokinetic interactions were observed among the major water-soluble constituents in the Danshen injection. The content variation of PAL had the most significant effect on the pharmacokinetic behaviors of other major constituents. Furthermore, the pharmacokinetics of DSS and Sal B were the most susceptible to the content change of other components.
Chang
Bo-bo
BB
Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China.
Zhang
Lin
L
Cao
Wan-wen
WW
Cao
Yuan
Y
Yang
Wen-liang
WL
Wang
Yan
Y
Chen
Yuan-cheng
YC
Liu
Xiao-quan
XQ
D000818:Animals; D001547:Benzaldehydes / Q000737:chemistry / Q000493:pharmacokinetics; D001572:Benzofurans / Q000737:chemistry / Q000493:pharmacokinetics; D002109:Caffeic Acids / Q000737:chemistry / Q000493:pharmacokinetics; D002396:Catechols / Q000737:chemistry / Q000493:pharmacokinetics; D004365:Drugs, Chinese Herbal / Q000737:chemistry* / Q000493:pharmacokinetics*; D005260:Female; D007773:Lactates / Q000737:chemistry / Q000493:pharmacokinetics; D010618:Phenanthrolines / Q000737:chemistry* / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D027561:Salvia miltiorrhiza / Q000737:chemistry*; D053630:Depsides
D001547:Benzaldehydes; D001572:Benzofurans; D002109:Caffeic Acids; D002396:Catechols; D004365:Drugs, Chinese Herbal; D007773:Lactates; D010618:Phenanthrolines; C028972:dan-shen root extract; C005581:protocatechualdehyde; C066201:salvianolic acid A; C076944:salvianolic acid B; D053630:Depsides